Étudiant-chercheur étoile September 2015



Sherif Eltonsy

PhD student in Pharmacoepidemiology
Université de Montréal


Award-winning publication: Risk of congenital malformations for asthmatic pregnant women using a long-acting β₂-agonist and inhaled corticosteroid combination versus higher-dose inhaled corticosteroid monotherapy

Published in: Journal of Allergy and Clinical Immunology

 

Abstract

"Asthma is one of the most common serious diseases among women of childbearing age. Severe or uncontrolled asthma can increase the risk of pregnancy complications affecting the mothers and their newborns compared to controlled asthma. Among the important clinical decisions that physicians must make if asthma cannot be controlled with a low dose of inhaled corticosteroid (ICS) during pregnancy is whether to prescribe long-acting inhaled beta2-agonist (LABA) to supplement the current dose of ICS or to increase the dose of ICS. However, there has been no direct comparison of these treatment regimens to guide physicians in whether it is safer for the newborn to increase the dose of ICS during pregnancy or to add a LABA. My work supports the fetal safety of LABA with ICS combination in the management of persistent asthma during pregnancy, encouraging clinicians to prescribe either combination or ICS monotherapy to keep the mothers' asthma under control."

The reassuring results of Eltonsy's study provide scientific evidence to help physicians and mothers make evidence-based treatment decisions during pregnancy. They are meant to encourage women to continue to take their asthma medications when required to control their asthma symptoms during pregnancy, increasing the likelihood of healthy pregnancies and newborns.